ResearcherTango Therapeutics, Inc.Active in the last 2 years

Maxim Pimpkin

Provisional: name at one institution (moderate confidence, 0.60), identity_conf@1As of 8 November 2026

Known by name at one institution; no external author ID yet. Sources: ClinicalTrials.gov.

Their work

Papers: 0
Trials: 2
Grants: 0
Labs led: 0
Collaborators: 0

Papers, trials and grants by year

2023: 1 trial · 2024: none · 2025: 1 trial

Trials 2

Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients Study director NCT06922591 ↗
Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors Study director NCT05732831 ↗

Closest collaborators

No collaborators recorded.

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.